BioMedNewsBreaks

MondayFeb 28, 2022 1:47 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Recognized as Innovator of the Year, Awarded Top Honors for Innovation in MedTech, Life Sciences

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its receipt of the top award as Innovator of the Year at the LeicestershireLive Innovation Awards 2022 held on Feb. 24, 2022. In addition, the company was awarded top honors for Innovation in MedTech and Life Sciences. “We are gratified and honored to be chosen for these top awards by our community peers. The Leicestershire regions has truly inspirational people and teams at the technology forefront across numerous industries,” said Dr. Faz Chowdhury, CEO of…

Continue Reading

FridayFeb 25, 2022 12:08 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement for Sale of Cobourg Facility for CAD$16.5M

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a life sciences holding company dedicated to building a portfolio of assets and biotech solutions. The company has announced its entry into a firm agreement in connection with the sale of its former Cobourg, Ontario-based cannabis processing facility and the 64.43-acre property on which the facility is located (the “transaction”). In consideration of the purchase of the facility, the purchaser has agreed to pay a cash sum of CAD$16,500,000, including a deposit of CAD$660,000 (the “deposit”). FSD Pharma received the deposit on Feb. 24, 2022, and the transaction, which is subject…

Continue Reading

WednesdayFeb 23, 2022 1:55 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Producing What Was Thought to Be Implausible

Nemaura Medical (NASDAQ: NMRD) has long focused on its corporate mission to develop non-invasive wearable diagnostic devices designed to help diabetic and near-diabetic patients monitor blood glucose levels by measuring blood markers at the surface of the skin. Its revolutionary sugarBEAT(R) constant glucose monitoring (“CGM”) device provides users with non-invasive glucose monitoring. Recently, the company released the MiBoKo application, an offering that uses a non-invasive glucose sensor to determine users’ Metabolic Score, which is based on glucose tolerance or insulin resistance. Nemaura Medical’s efforts come amid a rise in the global diabetic population that has led to an exponential increase…

Continue Reading

WednesdayFeb 23, 2022 10:03 am

BioMedNewsBreaks – AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Achieves New Milestone, Opens Additional Revenue Stream

AREV Life Sciences (CSE: AREV) (OTC: AREVF) today announced completion of its fungi inoculation lab, colonizing and fruiting rooms. According to the update, the fruiting room has been populated with colonized blocks of Lion's Mane (Hericium erinaceus) containing bioactive substances with beneficial effects on the body, especially the brain, heart and gut. “This is another milestone achieved by the team. The fresh product and extract serve as an additional revenue stream providing a strategic and versatile raw material supply source for finished products,” AREV Life Sciences CEO Mike Withrow said in the press release. “Our product development and research efforts…

Continue Reading

TuesdayFeb 22, 2022 2:16 pm

BioMedNewsBreaks – Genesis Unicorn Capital Corp. (NASDAQ: GENQU) Announces Closing of IPO, Full Exercise of Over-Allotment Option

Genesis Unicorn Capital (NASDAQ: GENQU) recently announced the closing of its initial public offering of 7,500,000 units, each at $10.00. Each unit consists of one share of Class A common stock and one warrant entitling the holder to purchase one share of Class A common stock at a price of $11.50 per share. The underwriters fully exercised the over-allotment option for an additional 1,125,000 units on Feb. 15, 2022, which closed at the time of the closing of the offering. As a result, Genesis Unicorn Capital secured aggregate gross proceeds of $86,250,000 from the offering and over-allotment. The units began…

Continue Reading

ThursdayFeb 17, 2022 11:38 am

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Partners with University of Milan to Test, Evaluate New Line of Smart-Patch Wellness Products

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, will be collaborating with the University of Milan, Italy, on a new wellness line of topical patches. The partnership will be testing the permeation and effectiveness of the patches, which RYAH developed for its Smart Patch system. University scientists are focused on determining the permeation effectiveness of vitamin and nutraceutical patches as an alternative slow-release, nondigested solution to consumer intake; they will also use the RYAH Smart Patch “boost capability” to monitor and…

Continue Reading

ThursdayFeb 17, 2022 11:19 am

BioMedNewsBreaks – AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Expands Corporate Efforts as It Advances Closer to Market with Milestone Products

AREV Life Sciences (CSE: AREV) (OTC: AREVF) today announced new corporate acquisitions and maturation of multiple product lines being matched with appointments and expanding corporate capacity in the company’s scientific advisory committee and IP council. The company has appointed Douglas Sorocco to its scientific advisory committee and IP council and has extended services with Strategic Health Resources LLC. These moves come as AREV’s expanding consumer products and therapeutic innovations pipeline enters mature stages of development. “These new additions to AREV’s corporate efforts assure acceleration of the enterprise’s immediate goals as we come closer to market entry with milestone products,” said…

Continue Reading

WednesdayFeb 16, 2022 1:47 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Evolution to Commercial Sales to Health and Wellness Market Featured in Research Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. According to the piece, InMed achieved Q222 financial results that reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wellness market, with revenues of $0.3 million, all cannabichromene (“CBC”). “As of January, it also began selling cannabicitran (‘CBT’) to the health and wellness market,” notes the report. “The now-completed BayMedica acquisition boosts its product portfolio for rare cannabinoids and rounds…

Continue Reading

WednesdayFeb 16, 2022 1:28 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Adds Novel Molecule to Family of Psilocin Analogs

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has included a novel molecule — MYCO-005 — which has potential for heart-safe microdose enabling properties, to its psilocin analogs. The company submitted a patent application covering multiple families of psilocin analogs late last year, noting that these second-generation molecules address delivery and stability concerns with the first-generation compounds. According to the company, its research findings show the potential for a psilocin analog that may be considered a heart-safe microdose drug, which is a substance consumed at a low enough…

Continue Reading

TuesdayFeb 15, 2022 3:21 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Distinctive with Phased Approach to Novel Therapeutics Development

Mydecine (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, was featured in a recent Bell2Bell Podcast episode in which its co-founder, chairman and CEO Josh Bartch shared the company’s goals for the new year. Of note was Mydecine’s phased approach, which entails understanding the imperfections of initial formulations and then improving aspects such as the nature of half-life, controllability delivery time, onset time, anxiety associated with different molecules, etc., in order to make them more effective. This approach has set the company apart from its peers. A…

Continue Reading